IO Biotech Inc

NASDAQ IOBT

Download Data

IO Biotech Inc Market Capitalization on April 17, 2024: USD 98.82 M

IO Biotech Inc Market Capitalization is USD 98.82 M on April 17, 2024, a 38.91% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.
  • IO Biotech Inc 52-week high Market Capitalization is USD 133.74 M on August 16, 2023, which is 35.33% above the current Market Capitalization.
  • IO Biotech Inc 52-week low Market Capitalization is USD 125.35 K on February 29, 2024, which is -99.87% below the current Market Capitalization.
  • IO Biotech Inc average Market Capitalization for the last 52 weeks is USD 96.28 M.
NASDAQ: IOBT

IO Biotech Inc

CEO Dr. Mai-Britt Zocca Ph.D.
IPO Date Nov. 5, 2021
Location Denmark
Headquarters Ole Maaløes Vej 3, Copenhagen, Denmark, 2200
Employees 68
Sector Healthcare
Industry Biotechnology
Description

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Similar companies

ELYM

Eliem Therapeutics Inc

USD 4.56

-4.00%

MNOV

MediciNova Inc

USD 1.52

-1.30%

IPSC

Century Therapeutics Inc

USD 3.14

-14.44%

LYRA

Lyra Therapeutics Inc

USD 5.40

2.47%

GLUE

Monte Rosa Therapeutics Inc

USD 6.06

-7.76%

CGEM

Cullinan Oncology LLC

USD 17.32

4.65%

CMPX

Compass Therapeutics Inc.

USD 1.57

-0.63%

DSGN

Design Therapeutics Inc

USD 3.69

-2.64%

HOWL

Werewolf Therapeutics Inc

USD 5.61

2.19%

STOK

Stoke Therapeutics Inc

USD 12.45

1.97%

StockViz Staff

April 18, 2024

Any question? Send us an email